A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 272 participants.

Also called NCT07755150

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 272 participants (planned count) (from the registry)
Sponsor
Chendu DIAO Pharmaceutical Group CO., LTD. (from the registry)
Registry
  • NCT NCT07755150
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07755150. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-30 (anticipated); primary completion 2027-10-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
DA-302168S
Intervention (Drug)
Placebo of DA-302168S
Lead sponsor
Chendu DIAO Pharmaceutical Group CO., LTD. (class: industry)

Record details

Record id
cardio:ct-nct07755150
Content hash
e1fe93027bf6320a615ae5cac293d1b59d5a5d5894418761be1e3eb4bfe5ad28